榮泰健康(603579.SH):擬3000萬元參與認購股權投資基金份額
格隆匯3月4日丨榮泰健康(603579.SH)公佈,在確保滿足日常經營資金需求、總體投資風險可控的前提下,為了進一步拓展投資領域,充分利用專業機構的經驗和資源,2025年3月3日,公司擬作為有限合夥人使用自有資金與普通合夥人兼執行事務合夥人蘇州維特力新創業投資管理有限公司(以下簡稱“維特力新”)及其他有限合夥人共同投資設立寧波甬元穩仲創業投資合夥企業(有限合夥),並簽訂了相關協議。合夥企業目標認繳總金額為人民幣100,000萬元,其中首次交割日後的初始認繳出資總額為人民幣50,000萬元(最終規模以實際募集金額為準),公司以自有資金認繳人民幣3,000萬元,持股比例佔合夥企業首期募集認繳出資總額的6.00%。合夥企業的投資領域主要為對以跨境電商、跨境貿易及/或輔助跨境電商與跨境貿易進行數字化改造和賦能為主營業務的企業進行價值投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.